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It is generally believed that bias is minimized in well-controlled
randomized clinical trials. However, bias can arise in active controlled
noninferiority trials because the inference relies on a previously esti-
mated effect size obtained from a historical trial that may have been
conducted for a different population. By implementing a likelihood
reweighting method through propensity scoring, a study designed to
estimate a treatment effect in one trial population can be used to
estimate the treatment effect size in a different target population.
We illustrate this method in active controlled noninferiority trials,
although it can also be used in other types of studies, such as histor-
ically controlled trials, meta-analyses, and comparative effectiveness
analyses.
1. Introduction. The code of federal regulations (CRF) Chapter 21, Sec-
tion 314.126, states that “The purpose of conducting clinical investigations
of a drug is to distinguish the effect of a drug from other influences. . .” and
the purpose is achieved through “adequate and well-controlled clinical in-
vestigation.” According to the CRF, an adequate and well-controlled trial
has a number of characteristics, including: (1) “The method of assigning
patients to treatment and control groups minimizes bias and is intended to
assure comparability of the groups with respect to pertinent variables such
as age, sex, severity of disease. . .” and (2) “Adequate measures are taken
to minimize bias on the part of the subjects, observers, . . . .” Characteristic
(1) and part of (2) aim to minimize bias through balancing the population
between the two treatment arms.
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By conducting well-controlled clinical trials, we generally anticipate that
systematic bias is minimized in superiority trials. However, this belief may
be more tenuous in noninferiority trials. Note that noninferiority trials are
the major vehicle to evaluate new treatments in many disease areas, after
the pioneering consideration of ethical issues in Placebo-controlled trials by
Rothman and Michels (1994).
Consider a Palivizumab-controlled noninferiority trial of Motavizumab for
prophylaxis of serious respiratory syncytial virus (RSV) disease in high risk
children [Carbonell-Estrany et al. (2010)]. This trial will be called MOTA
throughout the paper. The goal of the trial was to evaluate whether Mo-
tavizumab was noninferior to Palivizumab in the rate of hospitalization at-
tributed to RSV. Let µˆTC be the estimated log-odds ratio of Palivizumab
vs. Motavizumab, and let µˆCP be the estimated log-odds ratio of Placebo vs.
Palivizumab. Because the log-odds ratio of Placebo vs. Motavizumab can-
not be estimated directly (the noninferiority trial does not have a placebo
arm), µˆTC + µˆCP is often used as an indirect estimate, with a standard er-
ror of
√
σ2
TC
+ σ2
CP
. We may consider the noninferiority of Motavizumab to
Palivizumab to be met at level α if µˆ= (µˆTC + µˆCP )/
√
σ2
TC
+ σ2
CP
>Zα,
where Zα is the (100 − α)th percentile of a standard normal distribution.
In this example, µˆCP and its standard error σCP were obtained from an
earlier Placebo-controlled trial of Palivizumab, Impact-RSV Study Group
(1998), in which µˆCP = 0.86 (corresponding to odds ratio of 2.4) with a
standard error of 0.21. This trial will be called IMPACT throughout the
paper. Now, keeping in mind the fact that the statistics µˆ synthesizes µˆCP
and µˆTC , with the former estimated from the IMPACT population and the
latter estimated from the MOTA population, we illustrate the following is-
sues. First, both MOTA and IMPACT enrolled subjects exclusively from
two disjoint subgroups: (1) children ≤24 months with a clinical diagnosis of
Bronchopulmonary dysplasia (BPD); and (2) children with ≤35 weeks ges-
tation and ≤6 months, who did not have BPD. The proportion of subjects
with BPD was 51% in IMPACT and only 22% in MOTA. Second, treat-
ment heterogeneity of Palivizumab was observed in these two subgroups in
IMPACT. For subjects enrolled with BPD, the odds ratio was 4.88 with a
95% C.I. of (2.17,10.96), and for subjects enrolled without BPD, the odds
ratio was 1.72 a 95% C.I. of (1.06,2.79) (see Section 4). The Wald Chi-
square test of treatment by BPD interaction through a logistic regression
was significant with a p-value of 0.03. Because of the population differ-
ence and treatment heterogeneity, an appropriate odds ratio µˆCP used in
µˆ should reflect the population of MOTA, while the value of 0.86 instead
reflects the population of IMPACT. Using data provided in Section 4, we
obtain the adjusted incidence rate of Placebo in the MOTA population of
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34/266 × 22% + 19/234 × 78% = 9.2%, and the adjusted incidence rate of
Palivizumab of 39/496×22%+9/506×78% = 3.1%. Therefore, the adjusted
log-odds ratio is 1.14 and the adjusted odds ratio is 3.1. Consequently, the
adjusted log-odds ratio of Placebo vs. Palivizumab in the MOTA population
should be better quantified as 1.14 rather than 0.86, the unadjusted log-odds
ratio µˆCP . The difference between 1.14 and 0.86 is a bias associated with
this inference.
In the previous example, it was easy to adjust for the population dif-
ference, which only involved heterogeneity in BPD status. In some other
examples, the situation could be more complicated. For example, in the de-
velopment of Elvitegrevir [Molina et al. (2012)], the trial population was
different from the historical trial population in several characteristics, for
which treatment heterogeneity has been reported [Cooper et al. (2008)].
These examples show that analysis of a noninferiority trial may rely on
a combination of information from the trial itself and one or more histori-
cal trials. The main issue is that the populations of the noninferiority and
historical trials may be different. If treatment heterogeneity is present, an
inference that does not adjust for the population difference can be biased.
Covariate adjustment approaches [Zhang (2009) and Nie and Soon (2010)]
have been proposed to address the problem. Both approaches involve a re-
gression model relating the clinical outcome to treatment and relevant co-
variates. They cannot be directly applied to obtain the marginal (crude)
odds ratio, which is the prespecified primary endpoint in the aforementioned
examples.
This paper proposes a calibration method through likelihood reweight-
ing so that a study designed to estimate a marginal treatment effect size
for one trial population (e.g., IMPACT) may be used to calibrate the effect
size in a different but closely related study population (e.g., MOTA). We
prove that the maximum likelihood estimator for this reweighted likelihood
is a consistent estimator of the treatment effect size in the targeted popula-
tion. In addition, we also propose a nonparametric approach based on the
calibration method.
The proposed calibration approach using the likelihood reweighting method
is (asymptotically) equivalent to the covariate adjustment approach in some
cases such as linear regression, however, they are different in other cases.
The choice between the two approaches can be subtle and subjective. An
important consideration is to make sure that µˆTC and µˆCP in the statistics
µˆks = (µˆTC + µˆCP )/
√
σ2
TC
+ σ2
CP
have similar interpretations. Specifically,
if µˆTC is a marginal (i.e., overall) treatment effect as in the previous two
examples and in most randomized clinical trials, then µˆCP should probably
be calibrated using the method presented in this paper so as to maintain the
marginal interpretation. In Section 3.3 we also make some observations on
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the likelihood reweighing method as an alternative to the covariate adjust-
ment approach used in randomized clinical trials, along with the differences
noted in the literature.
Although this paper mainly targets noninferiority trials, the results are
also applicable to historically controlled trials, which have similar issues
[Friedman, Furberg and Demets (1998)]. A comparison of the likelihood
reweighting method to related methods in historically controlled trials, for
example, Zhang (2007), Signorovitch et al. (2010) and Signorovitch et al.
(2011), is provided in the supplement [Nie et al. (2013)]. This paper focuses
on calibrating the treatment effect size from one population to another pop-
ulation which is different but overlapping. It is related to but different from
studies generalizing results from a subpopulation to a strictly larger pop-
ulation (whole population); see Cole and Stuart (2010), Greenhouse et al.
(2008), Weisberg, Hayden and Pontes (2009) and Frangakis (2009), among
others. These references are restricted to the clinical trial literature, although
other areas, such as observational studies, involve similar problems.
2. Motivation, assumptions, and notation.
2.1. Motivation. The idea behind our method is simple. Recall the Intro-
duction where we obtained the expected incidence rate of Placebo in the
MOTA population as
12.8%× 22%+ 8.1%× 78% =
∑500
i=1 yipxi,MOTA/pxi,IMPACT
500
,
where pxi,MOTA and pxi,IMPACT are the percentage of Placebo subjects with
characteristics xi in MOTA and IMPACT trials, respectively. When xi = 1
(a diagnostic of BPD), the pxi,MOTA and pxi,IMPACT are 22% and 53%,
respectively; when xi = 0, they are 78% and 47%. By defining pxi,MOTA/
pxi,IMPACT as ri, the expected incidence rate of Placebo in the MOTA pop-
ulation is simply the mean of reweighted response from all subjects and
the weight reflects the change of population difference with respect to BPD
status.
In many other situations, the parameters cannot be directly calibrated as
shown in this example. They can, however, be estimated using a likelihood
approach to be described shortly.
Robins and colleagues gave an intuitive explanation of how the inverse
probability weighting approach reduces bias in the context of estimating
marginal structural models (MSMs) in epidemiology [Robins, Herna´n and
Brumback (2000)]. Heuristically, weighting each subject by the inverse of the
propensity score for the treatment actually received creates a confounding-
free pseudo-population, where treatment assignment is independent of the
potential outcomes. Typically, the inverse probability weighting approach
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is used to estimate marginal means of potential outcomes in an estimat-
ing equation framework. However, the insights of the work by Robins and
colleagues certainly extend to likelihood-based inference and allow us to cal-
ibrate the treatment effect. Specifically, upon appropriately reweighting the
likelihood function contributed by each subject, a calibrated treatment ef-
fect can be obtained. Before illustrating the reweighted likelihood approach,
we introduce some notation and assumptions.
2.2. Assumptions and notations. Consider a trial conducted in a pop-
ulation P (e.g., the IMPACT population) to compare treatment 1 (e.g.,
Palivizumab) to treatment 2 (e.g., Placebo). We assume that a random
sample from P is randomly assigned into these two treatment groups. The
objective of the trial is to quantify the treatment effect size of treatment
1 relative to treatment 2 in population P . The objective of this paper is
to calibrate the effect size of treatment 1 relative to treatment 2 from the
original population to a different but closely related population P ∗ (e.g.,
MOTA population).
We assume that the populations P and P ∗ are different. In our first
example, P refers to a population comprised of subjects with BPD (51%)
and without BPD (49%) and P ∗ refers to a population with a different
composition (22% with BPD, 78% without BPD).
We also assume that the populations P and P ∗ are closely related and
that the differences between P and P ∗ are entirely captured by the value
of a predictive covariate (vector) X representing subjects’ baseline disease
characteristics. In addition, we assume that all subjects with covariate value
X = x are expected to have the same treatment effect, regardless of their
origin (population P or population P ∗). That is, subjects with the same
covariate value X are exchangeable in P and P ∗. In our first example, this
means subjects with the same BPD diagnostic status, whether in the IM-
PACT population or the MOTA population, are exchangeable in terms of
response to treatments.
The difference and close relationship between population P and P ∗ is
further illustrated in mathematical form below after we clearly state the
objective of the paper. Let Y be the response variable. We write µt(X) =
E(Y |X,T = t) for the conditional mean response of subjects with covari-
ate X who were assigned into treatment T = t, and µtP = ν[EX∈P {µt(X)}]
for the transformed marginal mean response with respect to population P .
When ν(·) is the identity function, µtP is the marginal mean; when Y is
a binary variable and ν(·) is the logit function, µtP is the log odds in the
population P . µtP may be used to quantify the response of treatment T = t
from a historical trial, although this is not the focus of this paper but a
by-product. Instead this paper focuses on noninferiority trials, in which we
are interested in the treatment effect of treatment 1 vs. treatment 2. We
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thus consider µP = pi[EX∈P {µ1(X)},EX∈P {µ2(X)}] as a metric to measure
treatment effect of treatment 1 vs. treatment 2.
In the historical trial (e.g., IMPACT), µtP or µP is estimated. However,
the objective in this paper is to estimate µtP ∗ = ν[EX∈P ∗{µt(X)}] or µP ∗ =
pi[EX∈P ∗{µ1(X)},EX∈P ∗{µ2(X)}] through calibration, without conducting
a different trial in population P ∗ (MOTA population).
Let F (x) and F ∗(x) denote the cumulative distribution functions of X
in P and P ∗, respectively, and let f(x) and f∗(x) be the corresponding
probability density functions. We first assume that f∗(x)/f(x) 6= 1 for some
X = x, which illustrates the differences between populations P and P ∗. We
also assume that ∞> r(x) = f∗(x)/f(x) is well defined. Because the pop-
ulations are fully described by X , this assumption means that any subject
included in P ∗ should have representatives with the same measurements
in population P . This highlights the close relationship between P and P ∗.
When a value of x does not present in P ∗, then r(x) = 0. In this case, we
shall not use the subjects in the historical trials with value x.
3. Calibration of treatment effect size through likelihood reweighting.
In our first example only the BPD status is considered and the weight is
easy to define. However, in our second example many predictive covariates
may need to be considered. In the latter case, the definition of the weight is
straightforward using the concept of the propensity score [Rosenbaum and
Rubin (1983)].
3.1. Parametric approach. Assume two random samples of size n1, n2
from population P are assigned into treatment 1 and treatment 2, respec-
tively. We assume yit, the ith subject’s response from treatment group t,
follows a generalized linear model (GLM) with canonical link,
lt(y, θtx) = exp
{
yθtx − b(θtx)
atx(ϕtx)
+ ctx(y,ϕtx)
}
.(1)
Let g(·) be the canonical link function; then µt(X) = g−1(θt). We as-
sume that g(·) is a monotone function with continuous second derivative
functions. One possible metric to measure the treatment effect is EX(θtx)
and another possible metric is µtP = g[EX∈P {µt(X)}]. In the binomial-
logistic regression case, we implicitly assume that the log odds is additive
for the metric EX(θtx) and assume the proportion is additive for the metric
µtP = g[EX∈P {µt(X)}]. The former metric was used in the covariate adjust-
ment approach of Nie and Soon (2010). The latter metric shall be used in
the likelihood reweighting method, as introduced in this paper. These two
metrics are related but usually are not identical in nonlinear models.
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To estimate µtP , we construct the likelihood function
nt∏
i=1
lt(yit, αt).(2)
The maximum likelihood estimate (MLE) αˆt of αt is a consistent estimate
of the treatment effect size µtP = g[EX∈P {µt(X)}]. The proof for this is
standard and similar to that of Theorem 1 below, and is therefore omitted.
However, in this paper, our goal is to provide a consistent estimate of µtP ∗ =
g[EX∈P ∗{µt(X)}]. Our strategy is to “tilt” the population P so that it
matches the population P ∗ and our matching tool is the propensity score.
In the likelihood (2) we reweight the contribution of the likelihood func-
tion from the ith subject from the historical trial with the weight r(x), and
form a new likelihood function (2*)
nt∏
i=1
{lt(yit, αt)}r(xi).(2*)
Theorem 1. αˆ∗t , the MLE which maximize (2*), is a consistent estimate
of µtP ∗ = g[EX∈P ∗{µt(X)}]. In addition, αˆ∗t ∼N(µiP ∗ ,A−1(µiP ∗)B(µiP ∗)×
A−1(µiP ∗)), where
A(αt) = E
{
r(x)
d2 log lt(yit, αt)
dα2t
}
,
B(αt) = E
{
r2(x)
d log lt(yit, αt)
dαt
d logt(yit, αt)
dαt
}
.
The proof of Theorem 1 is given in the Appendix. Theorem 1 indicates
that the calibrated treatment effect converges to the treatment effect that
would be presented in population P ∗. In other words, the likelihood function
(2*) is reweighted in such a way that the units can be treated as randomly
sampled from a target population, not the population of the study. Note
that, if the two trials have the same population, then r(x) = 1, so that
likelihood function (2*) reduces to (2).
Briefly, we note that the parametric approach easily extends to include
some key covariates, including a treatment indicator as typically used in
noninferiority trials, in the likelihood (2*) as follows:
n∏
i=1
{l(yi, α+ βz)}r(xi),
where l(yi, α + βz) is the likelihood function contributed by the ith sub-
ject and z is a vector of treatment and/or covariate of interest. The MLE
converges to the parameters in the target population P ∗.
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3.2. Nonparametric approach. Section 3.1 is based on the model assump-
tion (1). In this subsection we take a nonparametric approach similar to the
reweighting method of Zhang (2007) [see also Signorovitch et al. (2010) and
Signorovitch et al. (2011)] for a historical control problem, and estimate
EX∈P ∗{µt(X)} by δˆt =
∑nt
i=1 yitr(xi)/
∑nt
i=1 r(xi). When nt→∞,∑nt
i=1 yitr(xi)
nt
→EX∈P
{
µt(X)
f∗(X)
f(X)
}
=EX∈P ∗{µt(X)}= µiP ∗.
Here we used the fact that r(x) = f∗(x)/f(x), shown in the proof of
Theorem 1 in the Appendix. Similarly,
∑nt
i=1 r(xi)/nt→EX{f∗(x)/f(x)}=
1. Therefore,
∑nt
i=1 yitr(xi)/nt→EX∈P ∗{µt(X)} and, thus,
µtP = ν[EX∈P {µt(X)}]
can be estimated by ν(δˆt) = v{
∑nt
i=1 yitr(xi)/
∑nt
i=1 r(xi)}. The variance of
the estimator and therefore the confidence interval for the desired parameter
can be obtained, for example, through the bootstrap method proposed in
Efron (1981).
3.3. Likelihood reweighting method vs. the previous covariate adjustment
approach. Aside from the differences between two approaches previously
mentioned in the Introduction, we have the following observations on the
likelihood reweighing method as an alternative to the covariate adjustment
approach used in randomized clinical trails, along with the differences noted
in the literature.
In the covariate adjustment approach, only the covariates interacting with
treatment are considered influential and relevant to the adjustment. How-
ever, there are other types of “influential” covariates. One type of “influ-
ential” covariates relates to noncollapsibility, as illustrated in Table 1 from
Greenland, Pearl and Robins (1999). Assuming that Table 1 represents the
population P and that X and Z represent the treatments and status of a
disease, 50% of enrolled subjects have a certain disease and the other 50%
of them do not have it. The event rates are 40% and 20% for treatment 1
(X = 1) and 2 (X = 0), respectively, in subjects with the disease and are
80% and 60% in subjects without the disease. The treatment 1 vs. treat-
ment 2 odds ratio is 2.67 whether subjects have the disease or not, hence
no treatment heterogeneity (i.e., no treatment by covariate interaction when
measured in odds ratio). Consider a population P ∗, in which 86% of enrolled
subjects have the disease and the other 14% of them do not have it. The
overall odds ratio in population P ∗ is thus 2.44. While the covariate ad-
justment approach would find that 2.67 is the odds ratio of treatment 1 vs.
treatment 2 in P and P ∗, the likelihood reweighting method would find that
2.25 and 2.44 are the odds ratio in P and P ∗, respectively. In other words,
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the covariate adjustment approach estimates the conditional odds ratio and
the likelihood reweighting method estimates the marginal odds ratio.
In this example, because the conditional odds ratio is not the same as the
marginal odds ratio, the issue of noncollapsibility arises, leading to some
questions on using the odds ratio as the measure of treatment effect. The
likelihood reweighting method provides a flexible way to circumvent this
difficulty. With the percentage difference as an alternative metric (measure
of treatment effect), we could work with τP ∗ = µ1P ∗ − µ2P ∗ and µtP ∗ =
ν[EX∈P ∗{µt(X)}], where ν(·) is the identity function.
The covariate adjustment approach relies on the ability of the data to
detect treatment effect heterogeneity, that is, the treatment by covariate
interaction. However, in some situations, trials may not be large enough to
detect moderate interactions because they are not designed for that pur-
pose. Even if some trials are large, the rarity of events could hamper the
ability to detect all heterogeneity. Therefore, it is likely that some impor-
tant interactions are not going to be detected, leading to partial adjustment
with a residual bias. In these scenarios, the likelihood reweighting method
can be a good alternative, as it estimates the marginal effect by maximiz-
ing the “unadjusted” likelihood (2*). Although modeling was also used to
estimate propensity scores, the dependent variable is the trial indicator, not
the outcome of interest.
The covariate adjustment approach may face co-linearity problems when
there are many covariates. When that happens, the model-based adjustment
requires a difficult decision on how to omit some covariates and select a good
model. When this problem occurs, the likelihood reweighting method can
be a good alternative, as it is less susceptible to this issue: while co-linearity
may also cause problems with parameter estimation in the propensity score
models, it does not adversely affect prediction of the propensity score itself.
The covariate adjustment approach utilizes the same outcome data for
both model selection and formal inference based on the chosen model, and
the results could be too optimistic. In case this becomes a concern, the like-
lihood reweighting method can be considered as an alternative, as propen-
sity score modeling and model selection do not involve outcome data. The
techniques presented here are expected to be useful in uncontrolled obser-
vational studies as well. Although uncontrolled observational studies inherit
many more issues than these controlled trials, the difference or change in the
patient populations associated to different comparing groups remains one of
the key issues.
As pointed out by the reviewers, a possible weakness of both approaches
is that they require subject-level data from the historical control trial. Read-
ers are referred to Nie and Soon (2010) for some discussions. One possible
solution could be defining the weight based on summary statistics, an idea
as illustrated in Signorovitch et al. (2010) and Signorovitch et al. (2011).
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4. Applications. In noninferiority trials, we aim to calibrate the effect
size of the active control (e.g., Palivizumab) relative to Placebo from the
historical trial population P (e.g., IMPACT) to the noninferiority trial pop-
ulation P ∗ (e.g., MOTA). Using Bayes’ rule, we obtain r(x) ∝ Pr(P ∗|X =
x)/Pr(P |X = x). As the population P ∗ is associated with the experimen-
tal treatment (e.g., Motavizumab) and the population P with Placebo,
r(x)∝ Pr(T =MOTA|X = x)/Pr(T = Placebo|X = x), that is, r(x) is pro-
portional to the odds through the propensity score.
4.1. Development of Motavizumab, a second generation of Palivizumab.
Palivizumab is a humanized monoclonal antibody, approved and marketed
for passive immunoprophylaxis of respiratory syncytial virus (RSV) in in-
fants at risk for serious RSV disease. It was studied in the IMPACT trial, a
phase III randomized, double-blind, Placebo-controlled clinical trial that was
conducted to evaluate the ability of prophylaxis with Palivizumab to reduce
respiratory syncytial virus infection in high-risk infants. A total of 1502 chil-
dren with prematurity or bronchopulmonary dysplasia (BPD), also called
chronic lung disease (CLD) in infancy, were randomized to receive either
Palivizumab or Placebo intramuscularly. The primary endpoint was RSV
related hospitalization within 150 days since administration of the first dose
of treatment. For more information of this trial please refer to the Impact-
RSV Study Group (1998). This trial enrolled subjects exclusively from two
disjoint subgroups: (1) children 24 months old or younger with a clinical di-
agnosis of BPD requiring ongoing medical treatment; and (2) children with
35 weeks gestation or less and 6 months old or younger, who did not have a
clinical diagnosis of BPD.
Among subjects enrolled with a diagnosis of BPD, the incidence rate of
RSV-related hospitalization was 12.8% (34/266) in the Placebo arm and
7.9% (39/496) in the Palivizumab arm. Among subjects enrolled without
a diagnosis of BPD, the incidence rate of RSV-related hospitalization was
8.1% (19/234) in the Placebo arm and 1.8% (9/506) in the Palivizumab arm.
Among the 500 subjects who received Placebo, 53 (10.6%) had an RSV-
related hospitalization; among the 1002 subjects who received Palivizumab,
48 (4.8%) had an RSV-related hospitalization (see Table 1 for details). It
is clear that the treatment effect of Palivizumab vs. Placebo was better in
subjects enrolled without a diagnosis of BPD than in subjects enrolled with
a diagnosis of BPD. The overall treatment effect size of Palivizumab, as
measured in the odds ratio of the Placebo vs. Palivizumab, was 2.4 with a
95% C.I. of (1.6,3.5).
To evaluate Motavizumab, a second generation version of Palivizumab,
a phase 3, randomized, double-blind, Palivizumab-controlled, multi-center,
multinational noninferiority trial (MOTA) was conducted to assess whether
Motavizumab was noninferior to Palivizumab. More precisely, the question
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Table 1
Subject distribution: numbers of subjects
(numbers of RSV-hospitalizations)
IMPACT trial BPD Non-BPD
Placebo 266 (34) 234 (19)
Palivizumab 496 (39) 506 (9)
MOTA trial
Palivizumab 723 (28) 2607 (34)
Motavizumab 722 (22) 2583 (24)
was whether Motavizumab is at least not too much worse than Palivizumab
in the sense that the difference of Motavizumab vs. Palivizumab is greater
than the difference of Placebo vs. Palivizumab. With the risk difference
metric this means that the rate difference of RSV hospitalization between
Motavizumab and Palivizumab is smaller than the rate difference of RSV
hospitalization between Placebo and Palivizumab. In the metric of odds ratio
this means that the odds ratio between Motavizumab and Palivizumab is
smaller than the odds ratio between Placebo and Palivizumab. In order to
evaluate noninferiority, one possible test statistic is
µˆks =
µˆTC + µˆCP√
σ2
TC
+ σ2
CP
,
where µˆTC is the overall log-odds ratio of Palivizumab vs. Motavizumab
and µˆCP is the overall log-odds ratio of Palivizumab vs. Placebo.
4.2. Calibrated effect size of Palivizumab vs. Placebo in the new MOTA
study population. Assume that Yixt, the incidence of RSV hospitalization of
the ith subject, follows a logistic regression model, yixt ∼ Binomail(1, pxt);
logit(pxt) = θxt with x = 0,1, representing subjects enrolled without and
with a diagnosis of BPD and t= 0,1 representing Placebo and Palivizumab.
Whether to make inference on pxt (the incidence rate) or θxt (the log odds
of an event) is generally subjective. Both are used extensively in noninfe-
riority trials. In IMPACT and MOTA, the log-odds ratio was the primary
metric, but the risk difference is the primary metric in current HIV trials.
Therefore, we shall illustrate both metrics in the Motavizumab example.
Let us first consider quantifying the treatment effect using the risk dif-
ference. Let pn denote the proportion of subgroup with x= 1 in the target
population (e.g., MOTA population) and ph denote the proportion of sub-
group with x= 1 in the historical population (e.g., IMPACT population). It
is easy to show that the MLEs of likelihood in (2) and (2*) are
αˆt =
n1ty¯·1t + n0ty¯·0t
n1t + n0t
; αˆ∗t =
n1t(pn/ph)y¯·1t + n1t((1− pn)/(1− ph))y¯·0t
n1t(pn/ph) + n1t(1− pn)/(1− ph)
.
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In our example, these are
αˆ0 =
266× 12.8%+ 234× 8.1%
500
= 10.6%;
αˆ∗0 =
(
266
0.22
266/500
12.8%+ 234
0.78
234/500
8.1%
)
/(
266
0.22
266/500
+ 234
0.78
234/500
)
= 9.1%.
Similarly, αˆ1 = 4.8%; αˆ
∗
1 = 3.1%. For the nonparametric approach pre-
sented in Section 3.2, the same results are obtained. Indeed, whether using
the risk difference or the log-odds ratio as metrics, the parametric approach
presented in Section 3.1 and the nonparametric approach presented in Sec-
tion 3.2 lead to the same results for this example.
The standard error of the calibrated effect size αˆ∗j can be calculated di-
rectly here as
std(αˆ∗0) =
√
0.222 × 12.8%× (1− 12.8%)
266
+ 0.782 × 8.1%× (1− 8.1%)
234
= 0.015.
Similarly, std(αˆ∗1) = 0.005. We could also use statistical software to obtain
the standard error. In this paper we used the SAS procedure PROC GEM-
MOD with the generalized estimating equation (GEE) option to compute
the standard error described in Theorem 1. The resulting standard errors
for αˆ∗0 and αˆ
∗
1 are 0.015 and 0.005, which are the same as obtained in our
direct computation.
Now, let us quantify the treatment effect using the log-odds ratio metric.
The estimate can be obtained through PROC NLMIXED with the repli-
cate statement. However, the standard error obtained from this procedure
is not the standard error stated in Theorem 1. In order to obtain the correct
standard errors, we could obtain a bootstrap standard error [Efron (1981)],
which is 0.25. Alternatively, we can also use PROC GEMMOD to obtain the
same point estimate and the standard error. It results in the same estimate
and standard error. Note that the unadjusted log-odds ratio is µˆCP = 0.86
with standard error 0.21.
The estimated log-odds ratio of Palivizumab vs. Motavizumab is 0.31
with a standard error of 0.20. Using the unadjusted or adjusted effect size,
we calculate the unadjusted and adjusted statistics,
µˆ=
µˆTC + µˆCP√
σ2
TC
+ σ2
CP
=
0.31 + 0.86√
0.202 + 0.212
= 4.0;
µˆadj =
µˆTC + µˆCP√
σ2
TC
+ σ2
CP
=
0.31 + 1.14√
0.202 + 0.252
= 4.5.
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The significance levels associated with the unadjusted and adjusted infer-
ence are 0.00003 and 0.000003, respectively. Other than this approach, one
can also use a more conservative approach, the fixed margin approach [see
FDA (2010) for details], to make the following inference:
µˆf =
µˆTC + µˆCP
σTC + σCP
=
0.31 + 0.86
0.20 + 0.21
= 2.9;
µˆadj,f =
µˆTC + µˆCP
σTC + σCP
=
0.31 + 1.14
0.20 + 0.25
= 3.2.
The significance level associated with the unadjusted inference is 0.002
and it is 0.0006 for the adjusted inference. Although both are less than 0.05,
the latter one is approximately 0.0252 , which means the significance level is
as low as that of two independent clinical trials, each significant at a level of
0.025, fulfilling the regulatory requirement on the quantity of the evidence
[see Soon et al. (2013)]. The quantity requirement has been interpreted in the
FDA guidance of drug effectiveness [FDA (1998)] as follows: “With regard
to quantity, it has been FDAs position that Congress generally intended to
require at least two adequate and well-controlled studies, each convincing
on its own, to establish effectiveness.” Therefore, the adjusted approach
could make a difference because Motavizumab was evaluated in a single
noninferiority trial. However, we emphasize that this analysis only takes
the published data into consideration and assumes that there are no other
potential issues associated with the trial design and conduct.
4.3. Calibrating the effect size using subject-level data. Section 4.2 pre-
sented a simple example to illustrate calibration through likelihood reweight-
ing. In general, subject-level data from a clinical trial is much more complex
than the data presented in Table 1. Although the FDA typically has access
to all subject-level data for regulatory purposes, we have no authority to
use them for purposes other than regulatory decision-making. Therefore, we
cannot share our experiences analyzing real data with readers. For the pur-
pose of illustrating methodology, we will use a simulated data set based on
the IMPACT data set and the MOTA data set.
We randomly generate variables x1, x2, and x3 so the generated data set,
say, IMPACT0 and MOTA0, will have 5 variables: BPD status, treatment,
x1, x2, and x3. In IMPACT0, we randomly generate a data set for 1502
subjects, with x1, x2,x3 following three independent Bernoulli distributions
with success rates of 0.4, 0.6, and 0.5. Similarly, in MOTA0, we randomly
generate another data set for 6635 subjects, with x1, x2, and x3 following
three independent Bernoulli distributions with success rates of 0.6, 0.5, and
0.4. We then pool the two data sets together and define a trial indicator to
distinguish IMPACT0 and MOTA0.
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To obtain the weight for each subject, we use logistic regression to model
the logit of the trial probability as a linear function of BPD status, x1, x2,
and x3. Using the fitted model, we predict the probability of each subject
in IMPACT0 being located in MOTA0. We then define the weight r(x) by
the odds of the predicted probability times 1502/6635. Note here vector
x means all variables: BPD status, treatment, x1, x2, and x3. Now, the
estimated propensity score ratio r(x) is defined for all 1502 subjects.
The MLE of the reweighted likelihood (2*) can be obtained through imple-
mentation of SAS procedure PROC GEMMOD (see the attached program-
ming code). With the repeat and weight statement [in the repeat statement,
subject is the ID number and the weight is r(x)], the GEMMOD procedure
provides the GEE [Zeger and Liang (1986)] type sandwich estimates for
standard error, corresponding to the variance formula given in Theorem 1.
All the programs, including the simulated data, are available upon request.
The point estimate of the adjusted log-odds ratio is 1.23 with a standard
error of 0.28. The final inference of the noninferiority trial may use the
following adjusted statistics:
µˆadj =
µˆTC + µˆCP√
σ2
TC
+ σ2
CP
=
0.31 + 1.23√
0.202 +0.282
= 4.5;
µˆadj,f =
µˆTC + µˆCP
σTC + σCP
=
0.31 + 1.23
0.20 + 0.28
= 3.2.
Although the problem did not occur in our example, we note that the
weighted likelihood approach may result in an estimate with large variance
if we have very small or very large values of r(x). The problem has been
described in the propensity score literature and is not unique to our setting.
Some promising methods for dealing with extreme propensity score weights
include using generalized boosted regression (GBR) [McCaffrey, Ridgeway
and Morral (2004), Ridgeway and McCaffrey (2007) and Lee, Lessler and
Stuart (2009)]. Based on our experience, we recommend that the propensity
score model should be limited to effect modifiers, that is, baseline variables
that are associated with the treatment difference, echoing what was recom-
mended by Cole and Herna´n (2008). Including many variables that are not
effect modifiers in the propensity score model generally increases the chance
of extreme weight due to the larger population heterogeneity, with no clear
benefits in reducing bias. The supplement [Nie et al. (2013)] provides more
details and a simulation study to illustrate this recommendation. At the end
of this section, we also describe some additional alternatives approaches.
Before doing that, we would like to discuss some special issues when this
problem occurs in historically controlled trials and noninferiority trials.
When the weights are extremely small, such as when some subjects with
certain characteristics in the historical trial have no or few counterparts
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(subjects with the same characteristics) in the noninferiority trials, r(x) is
0 or near 0 for these subjects. For example, this may happen when more
stringent inclusion criteria are implemented so that subjects with less severe
disease conditions at baseline were included in the historical trials but are
excluded from the noninferiority trial. It is understandable these subjects
(e.g., with less severe disease condition) may not always be used to make
inferences about the control vs. placebo (i.e., µˆCP ) in the noninferiority
trials subjects (e.g., with more severe disease condition) unless we make an
assumption that the treatment effect µˆCP in these subjects dose not depend
on baseline disease status. Only with this assumption, we may multiply their
weight r(x) using a large number so that these subjects still represent the
subjects with different characteristics. Without this assumption, the method
expectedly leads to a relatively larger variance because we discard a portion
of information from the historical trial.
The weights can be extremely large, such as when a subpopulation pre-
sented in a noninferiority trial is not well represented in the historical trial.
For example, some subjects in noninferiority trials of HIV may use a newly
approved potent background drug that was rarely used or never used in the
historical trials. In this case, using historical data from another group (sub-
jects who did not have the new background drug) to make inference about
the relative effect of the control vs. placebo (i.e., µˆCP ) may not be prudent
without additional assumptions. In this case, we might have to consider al-
ternative approaches. One possibility is to restrict the proposed analysis to
the subpopulation of the current study that is also represented in the histor-
ical study. This is essentially equivalent to what propensity score matching
would achieve, where unmatched subjects are automatically excluded. An-
other possibility is to consider the hybrid design idea presented in Soon et al.
(2011).
Now we briefly describe a stratified approach based on stratified propen-
sity scores. Suppose a control treatment is evaluated in historical trials but
we would like to calibrate its effect size in a new population for which r(x) is
computed. We group r(x) into a number of strata g1, . . . , gL. The percentage
of subjects falling into gl is wlh and wln in population P and P
∗, respec-
tively. Let βˆl with variances s
2
l be the treatment effect size in group l. Then
a combined calibrated treatment effect in the population P ∗ is
∑L
l=1 βˆlwln
with variance
∑L
l=1 s
2
lw
2
ln. When a new treatment is evaluated by its com-
parison to the control in population P ∗, a stratified analysis based on the
subclasses of the propensity score can be implemented as follows. Let γˆl be
an estimate of treatment effect of the new treatment, with variances s2ln,
in the lth group of the propensity score. We evaluate the new treatment
through a stratified analysis such as∑L
l=1{γˆl − βˆl}wl∗∑L
l=1{s2ln+ s2lh}w2l∗
.
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Depending on the objective, wl∗ may be chosen differently. Alternatively,
we may also use the stratification method as described in Section 4.3 or
define a threshold ∆2 >∆1 > 0 so that subjects with r(x) beyond [∆1,∆2]
should redefine the weight of [∆1,∆2], whichever is closer, similar to the
method used in Cole and Herna´n (2008). The actual determination of [∆1,∆2]
depends on the actual data and practical assumptions.
5. Concluding remarks. Motivated by a real example, we show that bias
can arise in active controlled noninferiority trials when estimated treatment
effect size for the control treatment is obtained from a historical trial that has
been conducted for a different population. Covariate adjustment approaches
[Zhang (2009) and Nie and Soon (2010)] have been proposed to address
the problem. However, they may be directly applied to obtain the marginal
treatment effects, which are often the pre-specified primary endpoints. This
paper proposes a likelihood reweighting method through propensity scoring
to estimate the marginal treatment effect size in the target population of a
noninferiority trial based on data obtained from a historical trial that has
been conducted for a different population.
APPENDIX
Proof of Theorem 1. It is easy to verify that the generalized linear
model satisfies Assumptions A1–A3 in White (1982), therefore, Theorem 2.2
is applicable. The log likelihood of (2*) is
n∑
i=1
f∗(xi)
f(xi)
log lt(yit, αt).
According to Theorem 2.2 [White (1982)], the maximum likelihood estimate
αˆt converges to the parameter, say, αt0, which maximizes∫
EY |X=x,T=t{log f(x) + log l(yit|x, t)− r(x) log l(yit, αt)}dF (x),
where log l(yit|x, t) is the log-likelihood function obtained from model (1).
Taking derivatives with respect to αt, we know αt0 is the solution of the
following equation:∫
EY |X=x,T=t[r(x){y− b′(αt)}]dF (x) = 0.
Consequently, the estimating equation can be written as∫
EY |X=x,T=t{y − b′(αt)}dF ∗(x) = 0.
Noting b′(·) = g−1(·), we have αt0 = µiP ∗ = g[EX∈P ∗{µt(X)}]. As the as-
sumptions A4–A6 are easily verifiable, the asymptotic properties of the MLE
of (2*) are immediately obtained from Theorem 3.2 in White (1982). 
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SUPPLEMENTARY MATERIAL
Supplement to “Likelihood reweighting methods to reduce potential bias
in noninferiority trials which rely on historical data to make inference”
(DOI: 10.1214/13-AOAS655SUPP; .pdf). The supplement provides an as-
sessment of the efficiency loss for the weighted likelihood method and a
comparison between the likelihood reweighting method and related meth-
ods in historically controlled trials.
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